October 14, 2016
EOS enters North African market, participates at the JFR
EOS imaging announced the recent entry into the North African market with the opening of two EOS sites in Tunisia.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 14, 2016
Dr. Li Zhou new TxCell’s Vice President Cell Engineering
TxCell SA has appointed Li Zhou, PhD, as Vice President, Cell Engineering.
October 14, 2016
SuperSonic presents new version of Aixplorer ultrasound system
SuperSonic Imagine presented the new version of Aixplorer, the UltraFast ultrasound system.
October 14, 2016
Safe Orthopaedics Reports Its Revenue for the First 9 Months
SAFE ORTHOPAEDICS has released its revenue for the first nine months of 2016 at September 30, 2016.
October 14, 2016
Sensorion reports €4.3M loss for first half of 2016
Net loss amounts to €4.3M at June 30, 2016, compared with a net loss of €1.5M at June 30, 2015.
October 14, 2016
IntegraGen Reports Loss for First Half of 2016
The net result over the first six months of 2016 was a loss of €1,028K compared to a loss of €872K in H1 2015.
October 14, 2016
Allergan partners with SonarMD in developing new IBS-D patient engagement platform
Allergan has announced a collaboration with SonarMD on the development of clinical decision support (CDS) and patient engagement tools which can be used to facilitate physician identification of patients suffering from Irritable Bowel Syndrome with Diarrhea (IBS-D) in clinical practice and monitor their treatment outcomes.
October 14, 2016
Aeterna Zentaris licenses its anti-cancer Zoptrex in Australia and New Zealand
Canadian biopharmaceutical company Aeterna Zentaris, Inc., has signed an additional licensing agreement with Specialised Therapeutics Asia (“STA”) for its anti-cancer compound, Zoptrex.
October 13, 2016
Horizon Pharma offers $300M senior notes and borrows money for buying Raptor Pharmaceuticals
Horizon Pharma, with its wholly owned subsidiaries, Horizon Pharma, Inc. and Horizon Pharma USA, Inc., intends to offer $300 million aggregate principal amount of senior notes due 2024, and to borrow $375 million.
October 13, 2016
Theradiag: Revenue growth at end September 2016 +31%
THERADIAG a company specializing in in vitro diagnostics and theranostics, has reported its consolidated revenues for the 3rd quarter of 2016.